Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808088 | 0.91 | PDE5A (0.45) | USP2PDE5ALMNAMAPK1ALDH1A1 | |
| SCHEMBL7090211 | 0.84 | PDE5A (0.42) | USP2PDE5ALMNAMAPK1ALDH1A1 | |
| SCHEMBL7838318 | 0.82 | PDE5A (0.41) | USP2PDE5ALMNAMAPK1ALDH1A1 | |
| SCHEMBL7660655 | 0.81 | LMNA (0.41) | USP2PDE5ALMNAALDH1A1TP53 | |
| SCHEMBL7966891 | 0.79 | PDE7A (0.50) | USP2PDE5ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5712364 | 0.78 | ALDH1A1 (0.59) | USP2PDE5ALMNAMAPK1ALDH1A1 | |
| SCHEMBL193613 | 0.77 | USP2 (0.47) | USP2LMNAMAPK1ALDH1A1TP53 | |
| SCHEMBL194662 | 0.77 | USP2 (0.47) | USP2LMNAMAPK1ALDH1A1TP53 | |
| SCHEMBL7495037 | 0.76 | LMNA (0.48) | LMNAALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL7498122 | 0.75 | LMNA (0.53) | LMNAMAPK1ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888359-B1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-05-02 | — | — | EP | claimed |
| EP-0888359-B1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| EP-1137649-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE DERIVATIVES | Syngenta Participations AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-20010018405-A1 | Process for preparation of pyrimidinone derivatives | WALTER HARALD (CH) | 2001-08-30 | — | — | US | disclosed |
| US-6262058-B1 | Pyrimidin-4-one derivatives as pesticide | SYNGENTA CROP PROTECTION, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-1087939-A1 | PROCESS FOR PREPARATION OF PYRIMIDINONE DERIVATIVES | Syngenta Participations AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000034286-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-06-15 | — | — | WO | disclosed |
| WO-1999067202-A1 | PROCESS FOR PREPARATION OF PYRIMIDINONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG . (CH) | 1999-12-29 | — | — | WO | disclosed |
| EP-0888359-A1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997033890-A1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | NOVARTIS AG (CH) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018405-A1 | Process for preparation of pyrimidinone derivatives | CBR1, CBR3, CYP4F8 | USP2 4195/4885PDE5A 2834/4885LMNA 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.